title: Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
authors.affiliation: Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland.
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
authors.forename: A G
authors.initials: AG
authors.lastname: Olsson
authors.forename: F M
authors.initials: FM
authors.lastname: Sacks
authors.forename: D M
authors.initials: DM
authors.lastname: Black
authors.forename: D G
authors.initials: DG
authors.lastname: Orloff
authors.forename: D W
authors.initials: DW
authors.lastname: Bilheimer
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D011859:Radiography; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids